Interventional Cardiology

This cardiac subspecialty uses minimally invasive, catheter-based technologies in a cath lab to diagnose and treat coronary artery disease (CAD). The main focus in on percutaneous coronary interventions (PCI) to revascularize patients with CAD that is causing blockages resulting in ischemia or myocardial infarction. PCI mainly consists of angioplasty and implanting stents. Interventional cardiology has greatly expanded in scope over recent years to include a number of transcatheter structural heart interventions.

CMS proposes Medicare coverage for transcatheter tricuspid valve replacement
Edwards Lifesciences sent a formal request to CMS in February after its Evoque TTVR device gained FDA approval. The agency is now accepting public comments for 30 days.
Hydra TAVR valve gains key approval as global reach continues to grow
The self-expanding device is now available in more than 20 countries and received CE mark approval back in 2020. However, it has not yet been approved by the U.S. Food and Drug Administration for use in the United States.
SAVR outperforms TAVR in patients with bicuspid aortic valves
BAV patients are often excluded from TAVR trials, creating uncertainty about the best way to treat that population when aortic valve replacement is required. To learn more, researchers tracked CMS data from 2018 to 2022, presenting their findings in The Annals of Thoracic Surgery.
Intravascular lithotripsy technology now a top priority for many healthcare companies
After the significant success of Shockwave Medical's IVL therapy to break up heavily calcified vessels without trauma, there are now several companies working on their own IVL devices.
SCAI president reviews achievements in interventional cardiology in 2024
SCAI President James Hermiller, MD, recently outlined the key achievements for 2024, including creation of the first interventional cardiology match program, successful advocacy and efforts to increase women in the field.

$The Neovasc Reducer System is designed to treat the symptoms of refractory angina by altering a patient's blood flow.$

Shockwave Medical to acquire medical device company for $100M

Shockwave Medical's decision to acquire Neovasc is based largely on the potential of the Neovasc Reducer System, a solution designed to treat the symptoms of refractory angina by altering a patient's blood flow.

January 17, 2023

Abbott has gained U.S. Food and Drug Administration (FDA) approval for its Navitor transcatheter aortic valve replacement (TAVR) system, the company’s new self-expanding valve for high-risk patients with severe symptomatic aortic stenosis.

Abbott receives FDA approval for new self-expanding TAVR system

The device, which gained CE mark approval in Europe in May 2021, features a new-look fabric cuff designed to keep the risk of paravalvular leak (PVL) at a minimum.

January 17, 2023

Fysicon’s QMAPP Hemodynamic Monitoring Device

Canon Medical Systems announces new partnership focused on enterprise imaging and hemodynamics

The partnership is with ScImage, a California-based healthcare technology company known for its extensive EI background.

January 16, 2023

How cardiologists can improve in-hospital outcomes after PCI

Researchers evaluated if two recently developed risk scores can anticipate adverse in-hospital outcomes after PCI, sharing their findings in the American Journal of Cardiology.

January 16, 2023

A new antiplatelet strategy for treating diabetic PCI patients

Clopidogrel monotherapy after just one month of DAPT was associated with promising outcomes, including a reduction in bleeding events.

January 13, 2023

How intravascular lithotripsy can improve TMVR outcomes

The IVL technology developed by Shockwave Medical helped clinicians treat a TMVR patient who had previously undergone TAVR. Could this be a common use of IVL in the future?

January 12, 2023